Veneno Technologies was selected for the second cohort of the J-StarX Biotech Accelerator Program, run by the Japan External Trade Organization (JETRO) and Texas Medical Center (TMC). The company took part in the on-site program in Houston, Texas, from September 21 to October 1, 2026.
At the Therapeutics Summit on September 30, CEO Takatoshi Kuno presented Veneno’s approach to using venom-derived disulfide-rich peptides (DRPs) to discover drug candidates for hard-to-target membrane proteins. Veneno will build on the connections made through the program to explore collaborations with U.S. research institutions, pharmaceutical companies, and biotechs.
Related link:
Read JETRO’s program recap (Japanese)
